(CENTA) Central Garden & Pet - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US1535272058
Stock: Pet Supplies, Garden Supplies, Seeds, Fertilizers, Treats
Total Rating 35
Risk 93
Buy Signal -2.28
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 31.9% |
| Relative Tail Risk | -15.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.06 |
| Alpha | -10.56 |
| Character TTM | |
|---|---|
| Beta | 0.555 |
| Beta Downside | 0.318 |
| Drawdowns 3y | |
|---|---|
| Max DD | 35.68% |
| CAGR/Max DD | -0.04 |
Description: CENTA Central Garden & Pet January 13, 2026
Central Garden & Pet Company (NASDAQ:CENTA) manufactures and distributes a broad portfolio of lawn-and-garden and pet-care products across the United States, operating through two distinct segments: Pet and Garden. The Pet segment, which includes brands such as K&H, Nylabone, and Kaytee, covers everything from dog treats and toys to aquariums and equine supplies. The Garden segment, featuring names like Ferry-Morse and Pennington, offers seeds, fertilizers, bird-feeding accessories, and chemical pest controls. Products reach consumers via independent distributors, big-box retailers, e-commerce platforms, grocery chains, and specialty nurseries.
Key recent metrics (FY 2023): revenue of roughly $2.3 billion, with the Pet segment contributing about 70 % of sales; gross margin near 38 %; and diluted EPS of $0.95. The U.S. pet market is expanding at an estimated 5 % CAGR, driven by higher discretionary spending and the “human-of-the-pet” trend, while the DIY garden segment benefits from seasonal consumer spending but remains sensitive to weather patterns and input-cost inflation (e.g., fertilizer prices).
For a deeper, data-driven look at CENTA’s valuation and scenario analysis, check out the ValueRay profile.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 162.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -2.03 > 1.0 |
| NWC/Revenue: 45.94% < 20% (prev 42.85%; Δ 3.09% < -1%) |
| CFO/TA 0.09 > 3% & CFO 332.5m > Net Income 162.8m |
| Net Debt (557.8m) to EBITDA (352.8m): 1.58 < 3 |
| Current Ratio: 3.67 > 1.5 & < 3 |
| Outstanding Shares: last quarter (62.4m) vs 12m ago -6.60% < -2% |
| Gross Margin: 31.87% > 18% (prev 0.29%; Δ 3159 % > 0.5%) |
| Asset Turnover: 87.88% > 50% (prev 91.55%; Δ -3.68% > 0%) |
| Interest Coverage Ratio: 4.64 > 6 (EBITDA TTM 352.8m / Interest Expense TTM 57.7m) |
Altman Z'' 4.54
| A: 0.40 (Total Current Assets 1.98b - Total Current Liabilities 538.8m) / Total Assets 3.63b |
| B: 0.28 (Retained Earnings 1.02b / Total Assets 3.63b) |
| C: 0.08 (EBIT TTM 267.9m / Avg Total Assets 3.56b) |
| D: 0.50 (Book Value of Equity 1.01b / Total Liabilities 2.04b) |
| Altman-Z'' Score: 4.54 = AA |
Beneish M -3.16
| DSRI: 1.02 (Receivables 325.3m/326.2m, Revenue 3.13b/3.20b) |
| GMI: 0.90 (GM 31.87% / 28.73%) |
| AQI: 1.00 (AQ_t 0.29 / AQ_t-1 0.29) |
| SGI: 0.98 (Revenue 3.13b / 3.20b) |
| TATA: -0.05 (NI 162.8m - CFO 332.5m) / TA 3.63b) |
| Beneish M-Score: -3.16 (Cap -4..+1) = AA |
What is the price of CENTA shares?
As of February 04, 2026, the stock is trading at USD 31.22 with a total of 262,993 shares traded.
Over the past week, the price has changed by +7.06%, over one month by +7.17%, over three months by +11.14% and over the past year by +0.45%.
Over the past week, the price has changed by +7.06%, over one month by +7.17%, over three months by +11.14% and over the past year by +0.45%.
Is CENTA a buy, sell or hold?
Central Garden & Pet has received a consensus analysts rating of 4.00.
Therefore, it is recommended to buy CENTA.
- StrongBuy: 3
- Buy: 1
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CENTA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 42.5 | 36.1% |
| Analysts Target Price | 42.5 | 36.1% |
| ValueRay Target Price | 31 | -0.6% |
CENTA Fundamental Data Overview February 02, 2026
P/E Trailing = 12.0275
P/E Forward = 10.7296
P/S = 0.6224
P/B = 1.2067
P/EG = 2.54
Revenue TTM = 3.13b USD
EBIT TTM = 267.9m USD
EBITDA TTM = 352.8m USD
Long Term Debt = 1.19b USD (from longTermDebt, last quarter)
Short Term Debt = 56.9m USD (from shortTermDebt, last quarter)
Debt = 1.44b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 557.8m USD (from netDebt column, last quarter)
Enterprise Value = 2.51b USD (1.95b + Debt 1.44b - CCE 882.5m)
Interest Coverage Ratio = 4.64 (Ebit TTM 267.9m / Interest Expense TTM 57.7m)
EV/FCF = 8.61x (Enterprise Value 2.51b / FCF TTM 291.1m)
FCF Yield = 11.62% (FCF TTM 291.1m / Enterprise Value 2.51b)
FCF Margin = 9.30% (FCF TTM 291.1m / Revenue TTM 3.13b)
Net Margin = 5.20% (Net Income TTM 162.8m / Revenue TTM 3.13b)
Gross Margin = 31.87% ((Revenue TTM 3.13b - Cost of Revenue TTM 2.13b) / Revenue TTM)
Gross Margin QoQ = 28.98% (prev 34.55%)
Tobins Q-Ratio = 0.69 (Enterprise Value 2.51b / Total Assets 3.63b)
Interest Expense / Debt = 1.00% (Interest Expense 14.4m / Debt 1.44b)
Taxrate = 24.35% (52.8m / 216.8m)
NOPAT = 202.6m (EBIT 267.9m * (1 - 24.35%))
Current Ratio = 3.67 (Total Current Assets 1.98b / Total Current Liabilities 538.8m)
Debt / Equity = 0.91 (Debt 1.44b / totalStockholderEquity, last quarter 1.58b)
Debt / EBITDA = 1.58 (Net Debt 557.8m / EBITDA 352.8m)
Debt / FCF = 1.92 (Net Debt 557.8m / FCF TTM 291.1m)
Total Stockholder Equity = 1.56b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.57% (Net Income 162.8m / Total Assets 3.63b)
RoE = 10.45% (Net Income TTM 162.8m / Total Stockholder Equity 1.56b)
RoCE = 9.74% (EBIT 267.9m / Capital Employed (Equity 1.56b + L.T.Debt 1.19b))
RoIC = 7.37% (NOPAT 202.6m / Invested Capital 2.75b)
WACC = 4.90% (E(1.95b)/V(3.39b) * Re(7.96%) + D(1.44b)/V(3.39b) * Rd(1.00%) * (1-Tc(0.24)))
Discount Rate = 7.96% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 8.11%
[DCF Debug] Terminal Value 85.48% ; FCFF base≈315.4m ; Y1≈290.7m ; Y5≈261.6m
Fair Price DCF = 143.7 (EV 7.88b - Net Debt 557.8m = Equity 7.32b / Shares 51.0m; r=5.90% [WACC]; 5y FCF grow -9.81% → 2.90% )
EPS Correlation: -19.77 | EPS CAGR: -38.58% | SUE: -2.21 | # QB: 0
Revenue Correlation: -7.37 | Revenue CAGR: 0.67% | SUE: 0.71 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.08 | Chg30d=-0.013 | Revisions Net=-1 | Analysts=4
EPS current Year (2026-09-30): EPS=2.78 | Chg30d=-0.007 | Revisions Net=-1 | Growth EPS=+1.8% | Growth Revenue=+0.1%
EPS next Year (2027-09-30): EPS=2.97 | Chg30d=-0.002 | Revisions Net=-1 | Growth EPS=+6.7% | Growth Revenue=+2.0%
P/E Forward = 10.7296
P/S = 0.6224
P/B = 1.2067
P/EG = 2.54
Revenue TTM = 3.13b USD
EBIT TTM = 267.9m USD
EBITDA TTM = 352.8m USD
Long Term Debt = 1.19b USD (from longTermDebt, last quarter)
Short Term Debt = 56.9m USD (from shortTermDebt, last quarter)
Debt = 1.44b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 557.8m USD (from netDebt column, last quarter)
Enterprise Value = 2.51b USD (1.95b + Debt 1.44b - CCE 882.5m)
Interest Coverage Ratio = 4.64 (Ebit TTM 267.9m / Interest Expense TTM 57.7m)
EV/FCF = 8.61x (Enterprise Value 2.51b / FCF TTM 291.1m)
FCF Yield = 11.62% (FCF TTM 291.1m / Enterprise Value 2.51b)
FCF Margin = 9.30% (FCF TTM 291.1m / Revenue TTM 3.13b)
Net Margin = 5.20% (Net Income TTM 162.8m / Revenue TTM 3.13b)
Gross Margin = 31.87% ((Revenue TTM 3.13b - Cost of Revenue TTM 2.13b) / Revenue TTM)
Gross Margin QoQ = 28.98% (prev 34.55%)
Tobins Q-Ratio = 0.69 (Enterprise Value 2.51b / Total Assets 3.63b)
Interest Expense / Debt = 1.00% (Interest Expense 14.4m / Debt 1.44b)
Taxrate = 24.35% (52.8m / 216.8m)
NOPAT = 202.6m (EBIT 267.9m * (1 - 24.35%))
Current Ratio = 3.67 (Total Current Assets 1.98b / Total Current Liabilities 538.8m)
Debt / Equity = 0.91 (Debt 1.44b / totalStockholderEquity, last quarter 1.58b)
Debt / EBITDA = 1.58 (Net Debt 557.8m / EBITDA 352.8m)
Debt / FCF = 1.92 (Net Debt 557.8m / FCF TTM 291.1m)
Total Stockholder Equity = 1.56b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.57% (Net Income 162.8m / Total Assets 3.63b)
RoE = 10.45% (Net Income TTM 162.8m / Total Stockholder Equity 1.56b)
RoCE = 9.74% (EBIT 267.9m / Capital Employed (Equity 1.56b + L.T.Debt 1.19b))
RoIC = 7.37% (NOPAT 202.6m / Invested Capital 2.75b)
WACC = 4.90% (E(1.95b)/V(3.39b) * Re(7.96%) + D(1.44b)/V(3.39b) * Rd(1.00%) * (1-Tc(0.24)))
Discount Rate = 7.96% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 8.11%
[DCF Debug] Terminal Value 85.48% ; FCFF base≈315.4m ; Y1≈290.7m ; Y5≈261.6m
Fair Price DCF = 143.7 (EV 7.88b - Net Debt 557.8m = Equity 7.32b / Shares 51.0m; r=5.90% [WACC]; 5y FCF grow -9.81% → 2.90% )
EPS Correlation: -19.77 | EPS CAGR: -38.58% | SUE: -2.21 | # QB: 0
Revenue Correlation: -7.37 | Revenue CAGR: 0.67% | SUE: 0.71 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.08 | Chg30d=-0.013 | Revisions Net=-1 | Analysts=4
EPS current Year (2026-09-30): EPS=2.78 | Chg30d=-0.007 | Revisions Net=-1 | Growth EPS=+1.8% | Growth Revenue=+0.1%
EPS next Year (2027-09-30): EPS=2.97 | Chg30d=-0.002 | Revisions Net=-1 | Growth EPS=+6.7% | Growth Revenue=+2.0%